Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 39

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 39
---
 classes or series of parity preferred stock upon which like voting rights have
been conferred and are exercisable).

So long as any shares of Series B Preferred
Stock remain outstanding, we will not, without the affirmative vote or written consent of the holders of at least two-thirds of the then
outstanding shares of Series B Preferred Stock and each other class or series of parity preferred stock with like voting rights (voting
together as a single class), authorize, create, issue or increase the number of authorized or issued shares of, any class or series of
equity shares ranking senior to the Series B Preferred Stock with respect to rights of dividend payments and the distribution of
assets upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, or reclassify any of our authorized equity
shares into such equity shares, or create, authorize or issue any obligation or security convertible into or evidencing the right to purchase
such equity shares. However, we may create additional classes of parity equity shares and junior equity shares, amend our charter and
the Articles Supplementary to increase the authorized number of parity equity shares (including the shares of Series B Preferred
Stock) and junior equity shares and issue additional series of parity equity shares and junior equity shares without the consent of any
holder of Series B Preferred Stock.

In addition, the affirmative vote or written consent
of the holders of at least two-thirds of the outstanding shares of Series B Preferred Stock and each other class or series of parity
preferred stock with like voting rights (voting together as a single class) is required for us to amend, alter or repeal any provision
of our charter so as to materially and adversely affect the terms of the Series B Preferred Stock. If such amendment to our charter
disproportionately affects the terms of the Series B Preferred Stock relative to the terms of one or more other classes or series
of parity preferred stock, the affirmative vote or written consent of the holders of at least two-thirds of the shares outstanding at
the time of Series B Preferred Stock, voting separately as a class, is required. Holders of the Series B Preferred Stock also
will have the exclusive right to vote on any amendment to our charter on which holders of the Series B Preferred Stock are otherwise
entitled to vote and that would alter only the rights, as expressly set forth in our charter, of the Series B Preferred Stock.

In any matter in which holders of Series B
Preferred Stock may vote (as expressly provided in the Articles Supplementary), each Series B Preferred